Oral agent in second-line more than doubled median PFS in patients with ESR1 muta ...

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...

Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML who have no satisfactory alternative treatment options, ...

Schizophrenia was associated with cardiac electrical instability, suggesting arrhythmic vulnerability was an intrinsic ...

FDA approval covers ER-positive/HER2-negative metastatic disease with ESR1 mutations after ≥1 endocrine line, with ...

Qualcomm reported that it earned a net income of $7.4 billion on revenues of $10.6 billion in the quarter ending March 29, ...

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1 ...

The global antibody drug conjugate (ADC) market size was valued at USD 13.51 billion in 2025 and is predicted to hit around ...

National Priority Vouchers aim to shorten FDA review from ~10–12 months to ~1–2 months using collaborative multidisciplinary ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from ...